26 March 2020 - Orphan Technologies today announced that OT-58 for the treatment of cystathionine beta synthase deficiency homocystinuria has been designated a rare paediatric disease by the US FDA.
OT-58 has previously been granted both fast track designation and orphan drug designation by the FDA.